ExelixisEXEL
EXEL
About: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,310
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
80% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 46
15% more capital invested
Capital invested by funds: $5.52B [Q2] → $6.37B (+$844M) [Q3]
9% more funds holding
Funds holding: 408 [Q2] → 445 (+37) [Q3]
1.61% more ownership
Funds ownership: 84.44% [Q2] → 86.05% (+1.61%) [Q3]
4% more call options, than puts
Call options by funds: $70.4M | Put options by funds: $67.6M
0% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 7 (+0) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 160
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
16%
downside
Avg. target
$34
3%
upside
High target
$40
20%
upside
12 analyst ratings
7 positive
58%
5 neutral
42%
0 negative
0%
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target | 20%upside $40 | Market Perform Downgraded | 20 Dec 2024 |
B of A Securities Jason Gerberry 43% 1-year accuracy 9 / 21 met price target | 17%upside $39 | Neutral Downgraded | 17 Dec 2024 |
Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target | 1%downside $33 | Buy Maintained | 30 Oct 2024 |
Stephens & Co. Sudan Loganathan 0 / 0 met price target | 13%downside $29 | Equal-Weight Maintained | 30 Oct 2024 |
Piper Sandler Joseph Catanzaro 32% 1-year accuracy 10 / 31 met price target | 8%upside $36 | Overweight Maintained | 30 Oct 2024 |
Financial journalist opinion
Based on 15 articles about EXEL published over the past 30 days
Positive
Zacks Investment Research
1 day ago
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
Positive
Zacks Investment Research
1 week ago
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
Zacks Investment Research
1 week ago
EXEL or INCY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
Positive
The Motley Fool
2 weeks ago
2 Biotech Stocks to Buy Hand Over Fist in December
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
3 weeks ago
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
3 weeks ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami. To access the w.
Positive
Zacks Investment Research
3 weeks ago
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
Neutral
Business Wire
3 weeks ago
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA is based on the final re.
Positive
Zacks Investment Research
3 weeks ago
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)
As the calendar winds down, the stock market often heats up. The last five weeks of the year have historically shown a bullish seasonal pattern, fueled by holiday optimism, institutional portfolio adjustments, and a tendency for investors to position themselves for the upcoming year.
Charts implemented using Lightweight Charts™